Huahai Pharma Obtains $14 Million in US Tariff Refunds
Zhejiang Huahai Pharmaceutical (SHA:600521) received tariff refunds worth $14.2 million through its subsidiary ScieGen Health USA, according to a Shanghai bourse filing on Thursday. The tariff refunds came after the U.S. Supreme Court ruled that the U.S. government's tariff measures were invalid and the amount should be refunded to importers. The refunds are expected to raise the pharmaceutical company's net profit for the year by 96.9 million yuan.
Story updates
09:25:07 AM UTC
SquawkNews
Zhejiang Huahai Pharmaceutical's (SHA:600521) U.S. subsidiary Solco Healthcare received tariff refunds of $14.2 million after the Supreme Court ruled tariffs imposed by the Trump administration under the International Emergency Economic Powers Act were invalid, according to a Thursday filing with the Shanghai bourse. The tariff refund represents 36% of the most recent audited net profit and could increase 2026 net profit by 96.9 million yuan.
2 million through its subsidiary ScieGen Health USA, according to a Shanghai bourse filing on Thursday. S. S. government's tariff measures were invalid and the amount should be refunded to importers.
9 million yuan.